查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853463

腫瘤NGS市場按產品類型、癌症類型、應用和最終用戶分類－2025-2032年全球預測

Oncology NGS Market by Product Type, Cancer Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腫瘤 NGS 市場將成長至 16.5064 億美元，複合年成長率為 15.97%。

主要市場統計數據
基準年 2024 5.0437億美元
預計年份：2025年 5.8357億美元
預測年份：2032年 16.5064億美元
複合年成長率 (%) 15.97%

全面闡述臨床定序創新、監管演變和營運協調如何融合，重新定義腫瘤學決策。

新一代定序 (NGS) 已從實驗室專屬技術發展成為癌症研究、診斷和治療開發的核心支柱。高性能儀器的引入、日益完善的生物資訊流程以及檢驗的臨床檢測方法，使得分子譜分析能夠指導診斷、預測治療反應並監測微小殘留病灶。隨著技術的融合，實驗室和臨床團隊正在採用連續定序，從標靶基因panel到全面的EXOME子組和轉錄組分析，不斷拓展從患者樣本中獲得的可操作資訊的範圍。

隨著科技的日趨成熟，監管管道和報銷機制也日趨完善，促使檢測驗證與臨床效用證據的產生更加緊密地結合。因此，相關人員正增加對營運流程、品管系統和資料管治的投入，以確保分析效能能夠轉化為可重複的臨床價值。這種環境形成了一個良性循環：檢測可靠性和解讀框架的提升推動了臨床應用，而臨床應用反過來又產生了支持NGS廣泛融入標準診療流程的真實世界證據。

鑑於科學的快速發展和醫療保健獎勵機制的不斷變化，各機構必須在短期營運調整與平台靈活性、試劑供應穩定性以及可擴展的生物資訊學方面的策略投資之間取得平衡。以下章節概述了變革性轉變、政策影響、競爭考察、區域動態、競爭洞察、實用建議以及支撐本分析的調查方法嚴謹性。

定序、資訊學和多組體學整合的技術進步如何重塑腫瘤學的診斷工作流程和臨床決策流程

在技​​術進步、數據整合和不斷演進的臨床範式的推動下，腫瘤定序領域正在經歷變革。短讀長定序平台持續最佳化成本和通量，而長讀長定序和單分子定序方法則顯著提升了以往難以分析的結構變異和複雜基因組區域的表徵能力。同時，檢測設計也從廣泛的探索性檢測轉向以臨床為導向，優先關注可操作的變異和預測性生物標記物，從而更快地轉化為治療方法的選擇。

資訊學已成為一項核心差異化優勢，雲端原生流程、容器化工作流程和機器學習輔助的變異解讀提高了周轉時間和解讀的一致性。這些能力與標準化報告架構的結合日益緊密，從而增強了不同機構間的可比較性。同時，去中心化趨勢正在加速發展。為了滿足多樣化的臨床需求並加快結果出爐速度，實驗室正在採用照護現場和床邊檢測策略，以補充集中式、高效能的營運。

最後，將包括RNA定序和表觀遺傳特徵在內的多組學資料與臨床和影像資料集整合，正在加速新型生物標記的發現和更精細的風險分層。因此，實驗室和供應商正在將資源轉向支援混合工作流程的模組化解決方案，以確保其投資在診斷模式不斷演變的過程中保持有效性。

調整營運應對措施和籌資策略，以因應基於關稅的供應鏈中斷，並提高2025年總到岸成本的透明度

政策變革和貿易行動會對整個診斷生態系統的供應鏈、成本結構和籌資策略產生重大影響。 2025年美國關稅政策為依賴全球化生產和複雜組件採購的實驗室、試劑生產商和儀器供應商帶來了新的考量。這些變化促使企業領導者重新評估供應商多元化、庫存管理和物流計劃，以降低跨境成本波動和潛在交貨延遲的風險。

為此，許多企業正在加快對替代供應商的資格審核，並調整庫存策略以確保服務不間斷。產品負責人也評估在地化生產和組裝的可行性，以減輕關稅的影響。同時，合約談判和服務水準協議也在進行修訂，以納入應對關稅波動和海關相關中斷的緊急條款。

重要的是，相關人員正優先考慮總落地成本計算的透明度和情境規劃，以了解政策動態可能如何影響融資和經常性試劑支出。透過綜合運用這些因應措施，動態旨在貿易政策加劇營運風險的環境下，既維持臨床工作的連續性，也維持財務可預測性。

詳細的細分洞察，包括產品類型、癌症類型、應用和最終用戶，揭示了影響檢測方法開發和商業化策略的差異化需求。

細分市場分析揭示了因產品類型、癌症類型、應用和最終用戶而異的細微需求和機會領域。按產品類型分類，平台需要為分散式臨床實驗室使用的桌上型定序儀以及支援大規模集中式操作的高性能定序儀進行資本規劃；試劑和耗材包括流動池、文庫製備試劑套件和定序試劑套件，這些產品具有不同的保存期限和低溫運輸要求；服務涵蓋資料分析和樣本製備服務，這些服務必須根據業務量和監管要求進行擴展。

乳癌的工作流程著重於荷爾蒙受體相關特徵和拷貝數分析；結直腸癌著重於微衛星不穩定性及腫瘤突變負荷評估；骨髓惡性腫瘤著重於融合基因檢測和克隆性分析；肺癌則需要敏感地檢測低頻驅動突變。每種癌症類型對檢測設計、驗證指標和臨床報告的要求各不相同。

從應用角度來看，基因panel可提供精準、可操作的見解，並廣泛用於選擇標靶治療。 RNA定序可檢測基因表現和融合基因，從而增強對變異的解讀和抗藥性機制的闡明；而全EXOME顯子定序則支持更廣泛的發現應用、種系-體細胞分化以及複雜生物標記的開發。從最終用戶的觀點，學術研究機構優先考慮靈活性和發現能力；診斷實驗室重視通量、可重複性和合規性；醫院將定序整合到臨床路徑中，並需要具備營運彈性；而製藥和生物技術公司則利用定序進行臨床檢測註冊、伴隨診斷開發和轉化研究。這些相互交織的領域會影響產品定位、檢驗藍圖和商業化策略。

區域動態和監管差異將影響定序能力、報銷模式和基礎設施投資如何影響全球臨床應用。

地理動態影響法律規範、報銷環境和營運模式，揭示了影響技術應用和投資的區域優先事項。在美洲，完善的報銷機制、成熟的參考實驗室網路以及活躍的臨床檢測活動正在推動臨床應用，支援集中式高效能定序和分散式診斷檢測。該地區支付方、醫療服務提供者和創新者之間的持續互動正在加速實證醫學證據的產生，並提高人們對臨床有效性和效用的期望。

歐洲、中東和非洲地區監管環境和醫療保健資金籌措模式的差異，造就了錯綜複雜的局面，國家政策決策和區域合作舉措共同決定一體化的步伐。實驗室必須因應不同的認證體系，並提供符合各國臨床指引的檢測服務。同時，該地區的相關人員正優先考慮數據標準的協調和互通性，以促進跨境研究和證據共享。

在亞太地區，定序基礎設施的快速投資、國內試劑生產的擴張以及強大的臨床檢測體係正推動著定序技術的顯著發展。多樣化的醫療保健系統和不同程度的集中式實驗室能力，既需要可擴展的高效能設施，也需要適應性強的桌上型解決方案。在所有地區，跨境合作、本地檢驗測試和監管協調對於加速將定序技術應用於常規癌症診療仍然至關重要。

競爭性創新、策略夥伴關係和能力整合如何推動腫瘤定序平台、試劑和服務供應商之間的差異化

企業間的競爭與合作動態正在塑造腫瘤定序生態系統的創新路徑與服務產品。現有平台供應商持續投資於儀器性能、通量最佳化和整合軟體，以降低臨床應用門檻。同時，試劑和耗材專家則專注於供應鏈彈性、檢測穩健性和跨多種儀器類型的相容性，以滿足不同實驗室的需求。服務供應商透過提供經過驗證的生物資訊產品、承包到報告工作流程以及臨床認證的實驗室能力來脫穎而出，從而減輕醫療專業人員的負擔。

共同開發契約正在加速伴隨診斷項目的推進，並有助於更有效地對患者進行分層，從而進行治療性檢測。新興企業正專注於滿足未被滿足的臨床需求的細分領域，例如超靈敏液態切片檢測、多組體學檢測和人工智慧驅動的解讀平台。同時，投資活動和有針對性的收購正在整合企業在規模和監管經驗方面的能力，從而獲得競爭優勢。

在此趨勢下，成功的公司正優先建構涵蓋可重複性、法規遵循、培訓、檢測驗證和上市後監測的客戶支援體系。這些能力增強了臨床醫生和支付方的信心，並在臨床證據和營運可靠性至關重要的市場中使供應商脫穎而出。

制定可操作的策略重點，協調平台模組化、生物資訊檢驗、供應鏈彈性以及相關人員參與，以加速臨床應用。

為了保持市場競爭力並加速造福患者，產業領導者必須將技術前景轉化為切實可行的、具有臨床意義的解決方案。首先，投資於平台相容性和試劑互通性可以降低客戶鎖定風險，並增強應對供應鏈中斷的能力。透過優先考慮模組化系統結構和開放資料實踐，企業可以實現技術在各種異質實驗室環境中的廣泛應用。

其次，加強生物資訊學和解讀能力至關重要。這意味著要投資檢驗的流程、標準化的變異註釋框架以及以臨床為中心的報告模板，從而縮短臨床醫生採取行動的時間。同樣重要的是，要為臨床醫生開發教育計畫和解讀支持，將基因組學觀察置於治療路徑中進行解讀。

第三，領導者應制定正式的供應商多元化和區域化策略，以降低關稅和物流風險。這可能包括尋找替代供應商、建立策略性庫存緩衝，以及在可行的情況下考慮本地化生產和組裝。此外，積極與監管機構和支付相關人員溝通，將確保證據的產生符合不斷變化的臨床效用和報銷預期。

最後，採用以客戶為中心的商業化策略，整合技術支援、檢驗服務和證據生成夥伴關係，將加速產品推廣應用。透過使產品藍圖與臨床工作流程和實驗室要求保持一致，企業可​​以提供不僅科學先進，而且在操作和經濟上都易於實現的解決方案。

採用嚴謹的混合方法，結合主要相關人員訪談、文獻回顧、使用案例分析和三角驗證，以獲得可靠且透明的見解。

本報告的分析綜合運用了多方面的證據，以確保其觀點穩健可靠。主要研究包括與實驗室主任、臨床基因組學負責人、採購負責人和行業高管進行結構化諮詢，以了解實踐規範、驗證要求和採購標準。此外，也對同儕審查文獻、臨床指南、監管文件和公開的技術文件進行了系統性回顧，從而提供有據可查的性能和臨床有效性，以此作為技術評估的依據。

我們運用定量和定性三角測量法，整合不同來源的數據，並分析具有代表性的實驗室實施方案，以深入了解工作流程最佳化、加快週轉時間和品管實踐。供應鏈和關稅影響分析包括海關裁決、貿易政策分析以及與物流專家的訪談，旨在評估潛在的營運應對措施和緩解策略。

為確保透明度，調查方法詳細記錄了資料來源、訪談通訊協定、納入標準和關鍵假設，並重點指出了監管時間表的區域差異和實驗室認證標準的異質性等限制。在適用情況下，數據透過與專家進行後續訪談進行檢驗，並與技術規格和已發布的臨床性能指標進行交叉核對。

全面分析技術成熟度、證據產生和供應鏈韌性將如何決定腫瘤定序常規臨床整合的路徑

總之，腫瘤特異性定序正處於曲折點，技術成熟度、數據整合和政策動態將共同決定其近期發展軌跡。定序化學和儀器設計的進步正在拓展分析能力，而資訊學和結果解讀的改進則提高了其臨床相關性。同時，與關稅相關的供應鏈問題和區域監管差異要求進行周密的營運規劃，以確保服務可靠交付。

這些措施包括投資於可互通的平台和檢驗的試劑，加強結果解讀流程，確保供應鏈多元化，以及在證據開發早期階段與監管機構和支付方進行溝通。對於臨床實驗室和醫療服務提供者而言，迫切需要將定序儀嵌入到可重複的工作流程和品質系統中，以便及時提供可操作的報告。對於開發人員和投資者而言，將產品開發與臨床效用和監管準備工作相結合，以確保產品被廣泛接受，是當務之急。

最終，將基因定序整合到常規腫瘤治療中將是一個循序漸進且以實證醫學主導。透過關注可重複性、臨床影響和供應穩定性，相關人員可以加快基因定序的普及應用，從而將科學進步轉化為可衡量的患者獲益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將液態生物檢體NGS檢測整合到多種癌症類型的早期檢測和治療反應監測中
  • 採用結合基因組學和轉錄組學分析的綜合腫瘤譜分析方案，以實現個人化腫瘤治療決策。
  • 人工智慧驅動的生物資訊平台的出現，簡化了科學研究和臨床實驗室對複雜癌症NGS資料集的解讀。
  • 利用可攜式定序儀擴展分散式NGS檢測，可在資源匱乏地區實現照護現場腫瘤診斷。
  • 利用新一代定序技術（NGS）識別可操作突變以確定合格接受標靶治療的伴隨診斷技術取得了成長。
  • 加強製藥公司與定序服務供應商之間的合作，以加速生物標記主導的藥物研發
  • 整合表觀遺傳學和蛋白質組學數據的多體學NGS方法在更好地理解腫瘤異質性方面取得了進展
  • 人們越來越關注基於NGS的腫瘤檢測的監管協調，以確保其全球市場進入和標準化。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按產品類型分類的腫瘤NGS市場

  • 平台
    • 桌上型音序器
    • 高通量定序儀
  • 試劑和耗材
    • 流動池
    • 圖書館調音套件
    • 定序試劑套件
  • 服務
    • 數據分析服務
    • 樣品製備服務

第9章：按癌症類型分類的腫瘤NGS市場

  • 乳癌
  • 大腸直腸癌
  • 造血系統惡性腫瘤
  • 肺癌

第10章：腫瘤NGS市場應用

  • 基因檢測
  • RNA定序
  • 全外EXOME定序

第11章：腫瘤NGS市場（依最終用戶分類）

  • 學術研究機構
  • 診斷實驗室
  • 醫院
  • 製藥和生物技術公司

第12章：腫瘤NGS市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腫瘤NGS市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國腫瘤NGS市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • BGI Genomics Co., Ltd.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • PerkinElmer, Inc.
    • Eurofins Scientific SE
    • Guardant Health, Inc.
    • Sophia Genetics SA
Product Code: MRR-3A2E844FECAB

The Oncology NGS Market is projected to grow by USD 1,650.64 million at a CAGR of 15.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 504.37 million
Estimated Year [2025] USD 583.57 million
Forecast Year [2032] USD 1,650.64 million
CAGR (%) 15.97%

A comprehensive orientation to how clinical sequencing innovations, regulatory evolution, and operational readiness are converging to redefine oncology decision making

Next-generation sequencing (NGS) has moved from an experimental capability to a core pillar of oncology research, diagnostics, and therapeutic development. The introduction of high-throughput instruments, increasingly robust bioinformatics pipelines, and validated clinical assays has enabled molecular profiling to inform diagnosis, predict therapeutic response, and monitor minimal residual disease. As technologies converge, laboratories and clinical teams are adopting sequencing across a continuum that spans targeted gene panels to comprehensive exome and transcriptome analyses, thereby expanding the scope of actionable insights derived from patient samples.

Alongside technological maturation, regulatory pathways and reimbursement conversations have become more sophisticated, prompting closer alignment between assay validation and clinical utility evidence generation. Consequently, stakeholders are investing in operational workflows, quality management systems, and data governance to ensure analytic performance translates into reproducible clinical value. This environment is creating a virtuous cycle: improved assay reliability and interpretive frameworks drive clinical adoption, which in turn generates real-world evidence that supports broader integration of NGS into standards of care.

Given the rapidly evolving science and shifting healthcare incentives, organizations must balance near-term operational readiness with strategic investments in platform flexibility, reagent supply resilience, and scalable bioinformatics. The following sections outline transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive considerations, pragmatic recommendations, and the methodological rigor underpinning the analysis.

How technological advances in sequencing, informatics, and multiomic integration are reshaping diagnostic workflows and clinical decision pathways in oncology

The oncology sequencing landscape is undergoing transformative shifts driven by technological breakthroughs, data integration, and evolving clinical paradigms. Short-read platforms have continued to optimize cost and throughput, while long-read and single-molecule approaches have advanced the characterization of structural variants and complex genomic regions that were previously refractory to analysis. Concurrently, assay design has shifted from broad, exploratory panels toward clinically focused content that prioritizes actionable variants and predictive biomarkers, enabling more rapid translation into therapeutic choices.

Informatics has emerged as a central differentiator, with cloud-native pipelines, containerized workflows, and machine learning-assisted variant interpretation improving turnaround times and interpretive consistency. These capabilities are increasingly coupled with standardized reporting frameworks that enhance cross-institutional comparability. At the same time, decentralization trends are accelerating: point-of-care and near-patient testing strategies are being piloted, complementing centralized high-throughput operations to meet diverse clinical needs and reduce time-to-result.

Finally, integration of multiomic data-including RNA sequencing and epigenetic signatures-with clinical and imaging datasets is catalyzing new biomarker discovery and refined risk stratification. As a result, laboratories and vendors are shifting resources toward modular solutions that support hybrid workflows, ensuring that investments remain relevant as diagnostic paradigms continue to evolve.

Operational responses and procurement strategies adapted to tariff-driven supply chain disruptions and increased total landed cost transparency in 2025

Policy changes and trade measures can materially affect supply chains, cost structures, and procurement strategies across the diagnostics ecosystem. Tariff actions in the United States in 2025 have introduced additional considerations for laboratories, reagent manufacturers, and instrument suppliers that rely on globalized production and complex component sourcing. These shifts have prompted operational leaders to reassess supplier diversification, inventory policies, and logistics planning to mitigate exposure to cross-border cost variability and potential delivery delays.

In response, many organizations have accelerated qualification of alternative suppliers and adjusted stocking strategies to maintain uninterrupted services. Procurement teams are increasingly specifying supplier redundancy and localized support as part of contracting criteria, while product developers are evaluating the feasibility of regionalized manufacturing or assembly to reduce tariff-related impacts. At the same time, contract negotiations and service-level agreements are being revisited to incorporate contingency clauses that address tariff volatility and customs-related disruptions.

Importantly, stakeholders are also prioritizing transparency in total landed cost calculations and scenario planning to understand how policy dynamics could influence capital procurement and recurring reagent expenditures. Through these combined responses, operators aim to preserve clinical continuity while maintaining financial predictability in an environment where trade policy represents an elevated operational risk.

Detailed segmentation insights revealing differentiated product, cancer-type, application, and end-user imperatives that shape assay development and commercialization approaches

Segment-level analysis reveals nuanced requirements and opportunity areas that vary by product type, cancer type, application, and end user. When examined through product type, platforms require capital planning for benchtop sequencers that serve decentralized clinical labs as well as high-throughput sequencers that underpin large centralized operations; reagents and consumables span flow cells, library preparation kits, and sequencing kits with distinct shelf-life and cold-chain demands; and services encompass data analysis services and sample preparation services that must scale with volume and regulatory expectations.

When viewed by cancer type, the diagnostic and therapeutic imperatives differ: breast cancer workflows emphasize hormone receptor-related signatures and copy-number analyses, colorectal cancer places a premium on microsatellite instability and tumor mutational burden assessments, hematological malignancies rely on fusion detection and clonality profiling, and lung cancer requires sensitive detection of low-frequency driver mutations. Each cancer type drives differentiated assay design, validation metrics, and clinical reporting priorities.

By application, gene panels deliver focused actionable insights and are widely used for targeted therapy selection, RNA sequencing provides expression and fusion detection that enhance variant interpretation and resistance mechanism elucidation, and whole exome sequencing supports broader discovery applications, germline-somatic differentiation, and complex biomarker development. From the perspective of end users, academic research institutes prioritize flexibility and exploratory capability; diagnostic laboratories focus on throughput, reproducibility, and regulatory compliance; hospitals integrate sequencing into clinical pathways and require operational resilience; and pharma and biotech companies leverage sequencing for trial enrollment, companion diagnostic development, and translational research. These intersecting segmentation axes inform product positioning, validation roadmaps, and commercialization strategies.

Regional dynamics and regulatory diversity shaping how sequencing capabilities, reimbursement models, and infrastructure investments influence clinical adoption globally

Geographic dynamics influence regulatory frameworks, reimbursement environments, and operational models, yielding distinct regional priorities that shape uptake and investment. In the Americas, clinical adoption is driven by established reimbursement pathways, a mature network of reference laboratories, and active clinical trial activity, which together support both centralized high-throughput sequencing and distributed diagnostic testing. Continuous interaction between payers, providers, and innovators in this region accelerates evidence generation while raising expectations for clinical validity and utility.

In Europe, Middle East & Africa, regulatory heterogeneity combined with divergent healthcare funding models fosters a mixed landscape in which national-level policy decisions and collaborative regional initiatives determine the pace of integration. Laboratories must navigate varied certification regimes and align assays with country-specific clinical guidelines. Meanwhile, stakeholders across this region emphasize harmonized data standards and interoperability to enable cross-border research and pooled evidence generation.

In the Asia-Pacific region, rapid investments in sequencing infrastructure, growing domestic reagent manufacturing, and strong clinical trial pipelines are driving significant momentum. Diverse healthcare systems and varying levels of centralized laboratory capacity create opportunities for both scalable high-throughput facilities and adaptable benchtop solutions. Across all regions, cross-border collaborations, local validation studies, and attention to regulatory alignment remain essential to accelerate the translation of sequencing into routine oncology care.

How competitive innovation, strategic partnerships, and capability consolidation are driving differentiation across platforms, reagents, and service providers in oncology sequencing

Competitive and collaborative dynamics among companies are shaping innovation pathways and service delivery across the oncology sequencing ecosystem. Established platform providers continue to invest in instrument performance, throughput optimization, and integrated software to lower barriers to clinical adoption. Meanwhile, reagent and consumable specialists are focusing on supply-chain resilience, assay robustness, and compatibility across multiple instrument types to appeal to diverse laboratory footprints. Service providers are differentiating through validated bioinformatics offerings, turn-key sample-to-report workflows, and clinically accredited laboratory capabilities that reduce burden for healthcare providers.

Strategic partnerships between technology vendors, clinical laboratories, and pharmaceutical developers are increasingly common, as co-development agreements accelerate companion diagnostic programs and enable more efficient patient stratification in therapeutic trials. Emerging companies are concentrating on niche areas such as ultra-sensitive liquid biopsy assays, multiomic panels, and AI-enhanced interpretation platforms that address unmet clinical needs. In parallel, investment activity and targeted acquisitions continue to consolidate capabilities where scale and regulatory experience deliver competitive advantage.

Across these dynamics, successful organizations are prioritizing reproducibility, regulatory readiness, and customer support infrastructure that spans training, assay validation, and post-market surveillance. These capabilities underpin trust among clinicians and payers and differentiate suppliers in a market where clinical evidence and operational reliability are decisive.

Actionable strategic priorities that align platform modularity, bioinformatics validation, supply resilience, and stakeholder engagement to accelerate clinical adoption

Industry leaders must translate technological promise into operationally viable, clinically meaningful solutions to retain market relevance and accelerate patient impact. First, investing in platform compatibility and reagent interoperability reduces customer lock-in risk and enhances resilience against supply-chain disruptions. By prioritizing modular system architectures and open-data formats, organizations can enable broader adoption across heterogeneous laboratory environments.

Second, strengthening bioinformatics and interpretation capabilities is essential. This means investing in validated pipelines, standardized variant curation frameworks, and clinically focused reporting templates that reduce time-to-action for clinicians. Equally important is the development of clinician-facing educational programs and interpretation support that contextualize genomic findings within treatment pathways.

Third, leaders should formalize supplier diversification and regionalization strategies to mitigate tariff exposure and logistics risk. This includes qualifying alternative vendors, building strategic inventory buffers, and exploring regional manufacturing or assembly where feasible. Additionally, proactive engagement with regulatory bodies and payer stakeholders will ensure that evidence generation aligns with evolving expectations for clinical utility and reimbursement.

Finally, adopting a customer-centric commercialization approach that bundles technical support, validation services, and evidence-generation partnerships will accelerate adoption. By aligning product roadmaps with clinical workflows and trial requirements, organizations can deliver solutions that are not only scientifically advanced but also operationally and economically accessible.

A rigorous mixed-methods approach combining primary stakeholder interviews, literature synthesis, case studies, and triangulation to ensure robust and transparent insights

The analysis underpinning this report combines multiple evidence streams to ensure a robust and defensible perspective. Primary research included structured consultations with laboratory directors, clinical genomics leads, procurement officers, and industry executives to capture operational realities, validation requirements, and procurement criteria. These inputs were complemented by a systematic review of peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available technical documentation to ground technology assessments in documented performance and clinical relevance.

Quantitative and qualitative triangulation methods were applied to reconcile disparate data sources, while case-study analyses of representative laboratory implementations provided practical insights into workflow optimization, turnaround-time drivers, and quality-control practices. The assessment of supply-chain and tariff impacts incorporated customs rulings, trade policy analyses, and logistics expert interviews to evaluate potential operational responses and mitigation strategies.

To ensure transparency, the methodology documents data sources, interview protocols, inclusion criteria, and key assumptions, and highlights limitations such as variability in regional regulatory timelines and heterogeneity in laboratory accreditation standards. Wherever applicable, data were validated through follow-up interviews with subject-matter experts and cross-checked against technical specifications and published clinical performance metrics.

Synthesis of how technology maturation, evidence generation, and supply-chain resilience collectively determine the path to routine clinical integration of oncology sequencing

In sum, oncology-focused sequencing is at an inflection point where technical maturity, data integration, and policy dynamics collectively determine near-term trajectories. Advances in sequencing chemistry and instrument design are expanding analytic capabilities, while improvements in informatics and interpretation are enhancing clinical relevance. At the same time, tariff-related supply-chain considerations and regional regulatory heterogeneity require deliberate operational planning to sustain reliable service delivery.

Organizations that succeed will be those that couple technological leadership with disciplined operational strategies: investing in interoperable platforms and validated reagents, strengthening interpretation pipelines, securing diversified supply chains, and engaging regulators and payers early in evidence development. For clinical laboratories and healthcare providers, the imperative is to embed sequencing within reproducible workflows and quality systems that deliver timely, actionable reports. For developers and investors, the priority is to align product development with clinical utility and regulatory readiness to ensure uptake.

Ultimately, the integration of sequencing into routine oncology care will be incremental and evidence-driven. By focusing on reproducibility, clinical impact, and supply resilience, stakeholders can accelerate adoption in ways that translate scientific progress into measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy NGS assays for early detection and monitoring of treatment response in diverse cancer types
  • 5.2. Adoption of comprehensive tumor profiling panels combining genomic and transcriptomic analysis for personalized oncology decisions
  • 5.3. Emergence of AI-driven bioinformatics platforms to streamline interpretation of complex cancer NGS datasets across research and clinical labs
  • 5.4. Expansion of decentralized NGS testing through portable sequencers enabling point-of-care oncology diagnostics in resource-limited settings
  • 5.5. Growth of companion diagnostic development using NGS to identify actionable mutations for targeted therapy eligibility
  • 5.6. Increasing collaboration between pharmaceutical companies and sequencing service providers to accelerate biomarker-driven drug development
  • 5.7. Advancements in multiomics NGS approaches integrating epigenetic and proteomic data for deeper understanding of tumor heterogeneity
  • 5.8. Rising focus on regulatory harmonization for NGS-based oncology tests to ensure global market access and standardization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology NGS Market, by Product Type

  • 8.1. Platforms
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High Throughput Sequencers
  • 8.2. Reagents And Consumables
    • 8.2.1. Flow Cells
    • 8.2.2. Library Prep Kits
    • 8.2.3. Sequencing Kits
  • 8.3. Services
    • 8.3.1. Data Analysis Services
    • 8.3.2. Sample Preparation Services

9. Oncology NGS Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Hematological Malignancies
  • 9.4. Lung Cancer

10. Oncology NGS Market, by Application

  • 10.1. Gene Panels
  • 10.2. Rna Sequencing
  • 10.3. Whole Exome Sequencing

11. Oncology NGS Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Pharma And Biotech Companies

12. Oncology NGS Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology NGS Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology NGS Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Roche Holding AG
    • 15.3.4. BGI Genomics Co., Ltd.
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Agilent Technologies, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. Eurofins Scientific SE
    • 15.3.9. Guardant Health, Inc.
    • 15.3.10. Sophia Genetics SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ONCOLOGY NGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY NGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GCC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 298. GCC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 299. GCC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 302. GCC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 303. GCC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. GCC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. BRICS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 330. BRICS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 332. BRICS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 333. BRICS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 334. BRICS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 335. BRICS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. BRICS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 341. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 342. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 343. G7 ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. G7 ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. G7 ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 346. G7 ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 347. G7 ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 348. G7 ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 349. G7 ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 350. G7 ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 351. G7 ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. G7 ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. G7 ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. G7 ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. G7 ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. G7 ONCOLOGY NGS MARKET SIZE, BY